Aptose Biosciences Inc. (TSX: APS) Aptose Biosciences Inc.
-
- Business
Podcast with news and updates from Aptose Biosciences (NASDAQ: APTO, TSX: APS), a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways.
-
William Rice, Aptose Biosciences: Clinical Programs in the Works
William Rice, Aptose Biosciences: Clinical Programs in the Works
-
William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic
William Rice, CEO and Greg Chow, CFO of Aptose Biosciences Molecule Expected to Return to Clinic